Redhill Biopharma - ADR

-0.03 (-3.64%)
5:03:52 PM EDT: $0.87 +0.02 (+2.20%)
Other Pre-Announcement

Redhill Biopharma Says Targeting Positive Cash From Operations To Start During H2/22

Published: 06/23/2022 11:15 GMT
Redhill Biopharma - ADR (RDHL) - Redhill Biopharma Ltd - Targeting Positive Cash From Operations to Start During H2/22.
Redhill Biopharma Ltd - Expected Operational Cost Savings of Approximately $50 Million Over Next 18 Months.
Redhill Biopharma Ltd - Net Revenues of $18.2 Million in Q1/22; Cash Balance of $45 Million As of March 31, 2022.
Redhill Biopharma Ltd - Opaganib and Rhb-107 Covid-19 Phase 3-stage Programs Expected to Be Funded Via External Sources.
Redhill Biopharma Ltd - Qtrly Loss per Ordinary Share, Basic and Diluted $0.03.
Redhill Biopharma - on June 17, Signed an Amendment to Hcr Credit Agreement Reducing Revenue Covenant to $75.0 Million for Next Two Quarters.